Pancreatic neuroendocrine tumors

Challenges in an underestimated disease

A. Viúdez, Ana De Jesus-Acosta, F. L. Carvalho, R. Vera, S. Martín-Algarra, N. Ramírez

Research output: Contribution to journalArticle

Abstract

Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.

Original languageEnglish (US)
Pages (from-to)193-206
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume101
DOIs
StatePublished - May 1 2016

Fingerprint

Neuroendocrine Tumors
Biomarkers
Molecular Targeted Therapy
Drug Therapy
Liver
Therapeutics

Keywords

  • Foregut
  • Gastrointestinal neuroendocrine tumors
  • Pancreas surgery
  • Pancreatic Neuroendocrine Tumor (PanNET)
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Pancreatic neuroendocrine tumors : Challenges in an underestimated disease. / Viúdez, A.; De Jesus-Acosta, Ana; Carvalho, F. L.; Vera, R.; Martín-Algarra, S.; Ramírez, N.

In: Critical Reviews in Oncology/Hematology, Vol. 101, 01.05.2016, p. 193-206.

Research output: Contribution to journalArticle

Viúdez, A. ; De Jesus-Acosta, Ana ; Carvalho, F. L. ; Vera, R. ; Martín-Algarra, S. ; Ramírez, N. / Pancreatic neuroendocrine tumors : Challenges in an underestimated disease. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 101. pp. 193-206.
@article{721398d17cb74f96b3b20e208ceb59d2,
title = "Pancreatic neuroendocrine tumors: Challenges in an underestimated disease",
abstract = "Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.",
keywords = "Foregut, Gastrointestinal neuroendocrine tumors, Pancreas surgery, Pancreatic Neuroendocrine Tumor (PanNET), Targeted therapies",
author = "A. Vi{\'u}dez and {De Jesus-Acosta}, Ana and Carvalho, {F. L.} and R. Vera and S. Mart{\'i}n-Algarra and N. Ram{\'i}rez",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.critrevonc.2016.03.013",
language = "English (US)",
volume = "101",
pages = "193--206",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Pancreatic neuroendocrine tumors

T2 - Challenges in an underestimated disease

AU - Viúdez, A.

AU - De Jesus-Acosta, Ana

AU - Carvalho, F. L.

AU - Vera, R.

AU - Martín-Algarra, S.

AU - Ramírez, N.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.

AB - Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.

KW - Foregut

KW - Gastrointestinal neuroendocrine tumors

KW - Pancreas surgery

KW - Pancreatic Neuroendocrine Tumor (PanNET)

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84964333741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964333741&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.03.013

DO - 10.1016/j.critrevonc.2016.03.013

M3 - Article

VL - 101

SP - 193

EP - 206

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -